SCHEMBL30135170

SCHEMBL30135170

C[C@H](CNC(=O)OC(C)(C)C)CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.47
PCSK9 Q8NBP7 1/20 0.47
SYK P43405 1/20 0.43
KCNA5 P22460 1/20 0.42
ALDH1A1 P00352 3/20 0.42
BRD4 O60885 1/20 0.41
CPB2 Q96IY4 1/20 0.40
TPSAB1 Q15661 1/20 0.40
TPSD1 Q9BZJ3 1/20 0.40
TPSG1 Q9NRR2 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361609 1.00 MALT1 (0.47) MALT1PCSK9SYKKCNA5ALDH1A1
SCHEMBL21359217 1.00 MALT1 (0.47) MALT1PCSK9SYKKCNA5ALDH1A1
SCHEMBL18085398 1.00 MALT1 (0.47) MALT1PCSK9SYKKCNA5ALDH1A1
SCHEMBL15570774 0.88 ALDH1A1 (0.49) MALT1SYKALDH1A1BRD4KMT2A
SCHEMBL15570773 0.88 ALDH1A1 (0.49) MALT1SYKALDH1A1BRD4KMT2A
SCHEMBL18085408 0.85 MALT1 (0.49) MALT1KCNA5BRD4TPSAB1TPSD1
SCHEMBL23102244 0.85 SYK (0.46) MALT1PCSK9SYKKCNA5ALDH1A1
SCHEMBL30500909 0.85 SYK (0.52) MALT1SYKALDH1A1BRD4MAPT
SCHEMBL20777647 0.84 MALT1 (0.45) MALT1SYKALDH1A1BRD4KMT2A
SCHEMBL29323153 0.83 MALT1 (0.47) MALT1KCNA5BRD4TPSAB1TPSD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 US disclosed
CN-112262129-B Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors 科智生命科学公司 2024-05-14 CN disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G MALT1 1465/4885PCSK9 184/4885SYK 3467/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MALT1 1573/4885PCSK9 275/4885SYK 3242/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS MALT1 180/4885PCSK9 2758/4885SYK 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.